press release

October 28, 2021

− Achieved Third Quarter 2021 Combined Net Product Revenues of $167 Million for ONPATTRO®, GIVLAARI®, and OXLUMO® – − Reported Positive Topline 18 Month Results from HELIOS A Phase 3 Study of Vutrisiran in hATTR Amyloidosis Patients with Polyneuropathy – – Completed Enrollment Ahead of Schedule in HELIOS B Phase 3 Study of Vutrisiran in ATTR Amyloidosis Patients with Cardiomyopathy – ...

press release

October 27, 2021

– Vutrisiran Met All 18 Month Secondary Endpoints, Including Statistically Significant Improvements in Progression of Neuropathy, Quality of Life (QOL), Gait Speed, Nutritional Status and Overall Disability, Relative to External Placebo – – At Month 18, Vutrisiran Also Showed Improvements in Exploratory Endpoints, Including Technetium Uptake Relative to Baseline in a Planned Cohort, Providing Potential Evidence for Reduced Cardiac Amyloid Burden ...

Web Page

October 25, 2021

Our Company CORPORATE RESPONSIBILITY Accepting Challenges to Improve the Health of Humanity Guided by the theme of “Accepting Challenges to Improve the Health of Humanity,” our approach to Corporate Responsibility informs our business strategy and ongoing work to address complex challenges and use our business as a force for good. By advancing innovations in medicines and access to care, we believe ...

Web Page

October 23, 2021

Our Company OUR LEADERSHIP The strength of our leadership has always been one of Alnylam’s greatest assets. Experience, tenacity, accountability, people focus and a commitment to the greater good are leadership traits we value and they’re reflected in our Management Team and Board of Directors. At Alnylam, we champion diversity, equity and inclusion and we seek to lead by example.Our Company ...

press release

September 13, 2021

− If Approved, Vutrisiran will Provide a New, Subcutaneously Administered, Once Quarterly Treatment Option for Patients with hATTR Amyloidosis − CAMBRIDGE, Mass. (BUSINESS WIRE) Sep. 13, 2021 Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for vutrisiran, an investigational RNAi therapeutic for ...

press release

September 7, 2021

- Subgroup Analyses and Exploratory Endpoints Demonstrated that Vutrisiran Improved Important Areas of Patient Health and Function Compared with Placebo at 9 Months – Additional Analyses Showed Similar Improvements in Progression of Neuropathy and Quality of Life Measures with Vutrisiran Treatment Compared with Placebo, Regardless of Prior TTR Stabilizer Use – Company Remains On Track to Announce Topline 18 Month Results, ...

news

August 4, 2021

"Innovation" is a term that’s used quite liberally in biotech, technology and a lot of other industries, but when you're creating something totally new, from scratch, as Alnylam has done with RNAi therapeutics, nearly everything that you do truly is an innovation. In our journey, some innovations were BIG and some were smaller, but through sustained research and development efforts over the past ...

press release

August 3, 2021

− Achieved Second Quarter 2021 Combined Net Product Revenues of $161 Million for ONPATTRO®, GIVLAARI®, and OXLUMO® – − Advanced Vutrisiran with New Drug Application (NDA) Submission to the U.S. Food and Drug Administration (FDA) for the Treatment of the Polyneuropathy of Hereditary ATTR Amyloidosis (hATTR PN); Received FDA Acceptance of NDA with Prescription Drug User Fee Act (PDUFA) Date Set ...

press release

July 29, 2021

− Agreement Combines PeptiDream’s Peptide Discovery Platform to Identify High Affinity Peptide Ligands with Alnylam’s Expertise in siRNA Conjugate Based Delivery and in Developing and Commercializing RNAi Therapeutics − CAMBRIDGE, Mass. & KAWASAKI CITY, Kanagawa Prefecture, Japan (BUSINESS WIRE) Jul. 29, 2021 Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, and PeptiDream, Inc. (Tokyo Stock Exchange: 4587), the ...

press release

June 30, 2021

– KARDIA 1 will Evaluate Efficacy and Safety of Quarterly and Biannual Regimens of Zilebesiran as Monotherapy – CAMBRIDGE, Mass. (BUSINESS WIRE) Jun. 30, 2021 Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced initiation of KARDIA 1, a global Phase 2 study evaluating the efficacy and safety of zilebesiran (pronounced “zile BEE siran” and formerly known ...